Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07280013 · ClinicalTrials.gov registry record · Phase 1
A Study to Learn About the Effects of Cemsidomide in Combination With Elranatamab in Relapsed/Refractory Multiple Myeloma Subjects
A Phase 1 study of Multiple Myeloma (MM), sponsored by C4 Therapeutics.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 60
- Enrollment target
- 19
- Study locations
NCT07280013: Recruiting Phase 1 study of Multiple Myeloma (MM), sponsored by C4 Therapeutics.
NCT07280013 is a Phase 1 study of Multiple Myeloma (MM) that is actively recruiting participants, run by C4 Therapeutics. The registered enrollment target is 60 participants, roughly in line with the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target. The trial reports 19 study locations across 17 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT07280013, a Phase 1 study of Multiple Myeloma (MM), is actively recruiting participants, sponsored by C4 Therapeutics.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 60 participants
- Enrollment target
- 19
- Study locations
Study Summary
The main purpose of the study is to understand the safety and tolerability of cemsidomide when given along with elranatamab in subjects with relapsed or refractory multiple myeloma. The first part of the study will evaluate different dose levels of cemsidomide in combination with elranatamab in a limited number of subjects. Approximately 3 different dose levels of cemsidomide in combination with elranatamab may be explored. Once a dose level is determined safe, additional subjects may be enrolled through expansion of the dose level. This expansion will provide further exploration of the safety and evaluation of preliminary antimyeloma activity. Cemsidomide will be taken orally each cycle for 14 days on/14 days off (1 cycle=28 days). Elranatamab will be administered by subcutaneous injection twice a month. Dexamethasone will be administered weekly until a confirmed response but no longer than 4 cycles.
Primary Outcome
Dose limiting toxicity rate
Conditions Studied
Interventions
- DRUG Cemsidomide
- BIOLOGICAL Elranatamab
Study Locations (19)
New York
- Perlmutter Cancer Center at NYU Langone Hospital - Brooklyn
- Memorial Sloan Kettering Cancer Center - New York
Texas
- Houston Methodist Hospital - Houston
- MD Anderson Cancer Center - Houston
Arizona
- Banner MD Anderson Cancer Center - Gilbert
California
- UCLA Health, Jonsson Comprehensive Cancer Center - Santa Monica
Florida
- Tampa General Hospital - Tampa
Georgia
- Winship Cancer Institute, Emory University - Atlanta
Illinois
- Loyola University Medical Center - Maywood
Indiana
- Indiana University - Indianapolis
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 60 participants |
| Start Date | 2026-02-06 |
| Est. Completion | 2029-06 |
| Phase | Phase 1 |
What NCT07280013 shows while recruiting
NCT07280013 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 60 participants, a relatively small participant target, roughly in line with the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target.
The record links to 1 condition, with Multiple Myeloma (MM) appearing as the primary indexed condition, and to 2 interventions - of which Cemsidomide is the first listed.
NCT07280013 lists 19 locations in 17 states (New York, Texas, Arizona).
Frequently Asked Questions
What is clinical trial NCT07280013 about?
NCT07280013 is a clinical study titled "A Study to Learn About the Effects of Cemsidomide in Combination With Elranatamab in Relapsed/Refractory Multiple Myeloma Subjects". The main purpose of the study is to understand the safety and tolerability of cemsidomide when given along with elranatamab in subjects with relapsed or refractory multiple myeloma. The first part of the study will evaluate different dose levels of cemsidomide in combination with elranatamab in a l...
What is the current status of trial NCT07280013?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 60 participants. The study started on 2026-02-06. Estimated completion is 2029-06.
What conditions does trial NCT07280013 study?
This clinical trial studies the following conditions: Multiple Myeloma (MM).
What interventions are being tested in trial NCT07280013?
The interventions under investigation include: Cemsidomide (DRUG), Elranatamab (BIOLOGICAL).
Who is sponsoring clinical trial NCT07280013?
This trial is sponsored by C4 Therapeutics, which has 5 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07280013 being conducted?
This trial has 19 study locations across Arizona, California, Florida, Georgia, Illinois. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Multiple Myeloma (MM)
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT07280013's enrollment target sits among peer trials
60 832nd of 2000 higher than 1,106 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00576069 · 60 participants
Mechanism(s)of Airflow Limitation in Moderate-severe Persistent Asthma
- NCT01297400 · 60 participants · Phase 2
Phase 2 Pilot Study of the Safety and Efficacy of Topical MW-III in Thermal Burns
- NCT01734122 · 60 participants
Stereotactic Radiosurgery for Essential Tremor and Parkinsonian Tremor
- NCT01804634 · 60 participants · Phase 2
Reduced Intensity Haploidentical BMT for High Risk Solid Tumors
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI